Date: March 22, 2024

To: Office of the Attorney General of Vermont

Re: Vermont New Drug Report

Via Email: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A. § 4637(c) Takeda Pharmaceuticals America is providing the following new drug report to the Office of the Attorney General of Vermont:

Description of New Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost (WAC) as of Date of Commercial Availability
Eohilia Oral Suspension 2 MG/10ML	64764-0105-60	02/20/2024	$1,875.00

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally
Takeda's marketing plans, including the spending associated with Takeda's marketing tactics, are confidential and proprietary, and not available in the public domain. However, marketing to support product launch will include print and digital media materials, including emails, a website for healthcare professionals, a website for patients, detailing materials for sales representatives to share information about Eohilia with appropriate prescribers, including for patient education, and attendance at professional congresses. Takeda used a value-based pricing methodology in setting the launch price of Eohilia, and considered several factors including, but not limited to: (i) the value the medicine brings to patients and society; (ii) the ability of patients to access our medicines; and (iii) our mission of continuing to develop, research, and market new medicines to address patients' unmet needs. For more information, please see Takeda's Pricing Philosophy.

The estimated volume of patients who may be prescribed the drug
Eohilia (budesonide), an orphan drug, is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). EoE is a chronic, immune-mediated disorder in which eosinophils accumulate in the esophagus, causing inflammation and edema to the surrounding tissue. Due to the nature of the disease for which Eohilia is indicated, Takeda has not determined a specific volume of patients for whom Eohilia may be prescribed, and therefore an estimated volume of patients in the US for whom Eohilia may be prescribed is not available in the public domain. However, one prevalence estimate by the National Organization for Rare Disorders (NORD) suggests that 1 in 2,000 people in the US live with EoE, which is approximately 166,000 cases.

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval
Yes, Eohilia was granted breakthrough therapy designation and priority review by the FDA prior to final approval.

Date and price of acquisition if the drug was not developed by the manufacturer
Not applicable.

For any questions concerning this notification please contact me at jessica.blain@takeda.com

Sincerely,

Jessica Blain

Associate Director, Contracts and Pricing Compliance

Takeda Pharmaceuticals America, Inc.
500 Kendall Street
Cambridge, MA 02421